Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;56(1):32-39.
doi: 10.1007/s00120-016-0274-3.

[PSMA-targeted radioligand therapy in prostate cancer]

[Article in German]
M M Heck  1 , M Retz  2 , R Tauber  2 , K Knorr  3 , C Kratochwil  4 , M Eiber  3
Affiliations
Review

[PSMA-targeted radioligand therapy in prostate cancer]

[Article in German]
M M Heck et al. Urologe A. 2017 Jan.

Abstract

Radioligand therapy (RLT) directed against prostate-specific membrane antigen (PSMA) enables tumor-specific treatment directed against PSMA-overexpressing prostate cancer cells. Several PSMA ligands such as PSMA-617 or PSMA-I&T have been developed that can be labeled with β‑radiating lutetium-177. These are currently applied in compassionate use programs to treat metastatic castration-resistant prostate cancer (mCRPC). PSMA-directed RLT is currently being offered in several nuclear medicine departments throughout Germany. Several retrospective case series demonstrate its activity with a prostate-specific antigen (PSA) decrease >50% in 30-60% of mCRPC patients. The toxicity seems to be low. Hematologic grade 4 toxicity has not been observed and grade 3 toxicities rarely occur. The main nonhematologic adverse events are intermittent dry mouth because of unspecific PSMA expression in the salivary glands as well as fatigue and nausea. Currently there are no prospective studies available for evaluation of PSMA-targeted RLT and a survival benefit over approved standard therapies such as abiraterone, enzalutamide, radium-223-dichloride, docetaxel or cabazitaxel has not been shown. PSMA-targeted RLT should therefore currently only be offered after critical evaluation in patients who exhausted the approved standard therapies.

Keywords: Hormone therapy; Metastasis; Radioligand therapy; Radiotherapy; Systemic therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Nucl Med. 2016 Sep;57(9):1334-8 - PubMed
    1. EJNMMI Res. 2015 Dec;5(1):114 - PubMed
    1. Cancer Res. 1994 Apr 1;54(7):1807-11 - PubMed
    1. Urology. 1996 Aug;48(2):326-34 - PubMed
    1. EJNMMI Res. 2014 Dec;4(1):63 - PubMed

MeSH terms

LinkOut - more resources